Lu Shao-Lun, Hsu Feng-Ming, Chen Kuan-Yu, Ho Chao-Chi, Yang James Chih-Hsin, Cheng Jason Chia-Hsien
Division of Radiation Oncology, Department of Medical Imaging, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu City, Taiwan.
Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
Case Rep Oncol. 2016 Aug 17;9(2):474-480. doi: 10.1159/000448804. eCollection 2016 May-Aug.
Maintenance pemetrexed offers survival benefit with well-tolerated toxicities for advanced non-squamous non-small cell lung cancer (NSCLC). We present 3 consecutively enrolled patients with advanced non-squamous NSCLC, receiving stereotactic ablative radiotherapy (SABR) for oligoprogressive disease during maintenance pemetrexed. All of them had sustained local control of thoracic oligoprogression after the SABR, while maintenance pemetrexed were kept for additionally long progression-free interval. SABR targeting oligoprogression with continued pemetrexed is an effective and safe approach to extend exposure of maintenance pemetrexed, thus maximizing the benefit from it.
培美曲塞维持治疗可为晚期非鳞状非小细胞肺癌（NSCLC）带来生存获益，且毒性耐受性良好。我们报告了3例连续入组的晚期非鳞状NSCLC患者，在培美曲塞维持治疗期间因寡进展性疾病接受了立体定向消融放疗（SABR）。所有患者在SABR后均实现了胸部寡进展的持续局部控制，同时继续进行培美曲塞维持治疗以延长无进展生存期。针对寡进展进行SABR并持续使用培美曲塞是一种有效且安全的方法，可延长培美曲塞的暴露时间，从而使其获益最大化。
